

Nimish Vakil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4198989/publications.pdf>

Version: 2024-02-01

149
papers

14,305
citations

43973

48
h-index

19136

118
g-index

155
all docs

155
docs citations

155
times ranked

8314
citing authors

#	ARTICLE	IF	CITATIONS
1	The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. <i>American Journal of Gastroenterology</i> , 2006, 101, 1900-1920.	0.2	3,207
2	Current concepts in the management of <i>Helicobacter pylori</i> infection: the Maastricht III Consensus Report. <i>Gut</i> , 2007, 56, 772-781.	6.1	1,706
3	A Controlled Trial of an Expansile Metal Stent for Palliation of Esophageal Obstruction Due to Inoperable Cancer. <i>New England Journal of Medicine</i> , 1993, 329, 1302-1307.	13.9	730
4	Development of the GerdQ, a tool for the diagnosis and management of gastroesophageal reflux disease in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 1030-1038.	1.9	497
5	ACG and CAG Clinical Guideline: Management of Dyspepsia. <i>American Journal of Gastroenterology</i> , 2017, 112, 988-1013.	0.2	431
6	Guidelines for the Management of Dyspepsia. <i>American Journal of Gastroenterology</i> , 2005, 100, 2324-2337.	0.2	411
7	A Global, Evidence-Based Consensus on the Definition of Gastroesophageal Reflux Disease in the Pediatric Population. <i>American Journal of Gastroenterology</i> , 2009, 104, 1278-1295.	0.2	367
8	Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A Cost-Utility Analysis. <i>Annals of Internal Medicine</i> , 2003, 138, 176.	2.0	330
9	Absence of Benefit of Eradicating <i>Helicobacter pylori</i> in Patients with Nonulcer Dyspepsia. <i>New England Journal of Medicine</i> , 1999, 341, 1106-1111.	13.9	323
10	Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. <i>Gut</i> , 2010, 59, 714-721.	6.1	281
11	A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. <i>American Journal of Gastroenterology</i> , 2001, 96, 1791-1796.	0.2	269
12	Sequential Therapy or Triple Therapy for <i>Helicobacter pylori</i> Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 3069-3079.	0.2	254
13	Sequential Therapy versus Standard Triple-Drug Therapy for <i>Helicobacter pylori</i> Eradication. <i>Annals of Internal Medicine</i> , 2007, 146, 556.	2.0	249
14	Global eradication rates for <i>Helicobacter pylori</i> infection: systematic review and meta-analysis of sequential therapy. <i>BMJ</i> , 2013, 347, f4587-f4587.	3.0	223
15	Eradication Therapy for <i>Helicobacter pylori</i> . <i>Gastroenterology</i> , 2007, 133, 985-1001.	0.6	217
16	The efficacy of proton pump inhibitors in nonulcer dyspepsia: A systematic review and economic analysis. <i>Gastroenterology</i> , 2004, 127, 1329-1337.	0.6	211
17	Limited Value of Alarm Features in the Diagnosis of Upper Gastrointestinal Malignancy: Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2006, 131, 390-401.	0.6	201
18	High eradication rates of <i>Helicobacter pylori</i> with a new sequential treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 719-726.	1.9	199

#	ARTICLE	IF	CITATIONS
19	Antimicrobial Resistance Incidence and Risk Factors among <i>Helicobacter pylori</i> "Infected Persons, United States. <i>Emerging Infectious Diseases</i> , 2004, 10, 1088-1094.	2.0	188
20	Empiric Quadruple vs. Triple Therapy for Primary Treatment of <i>Helicobacter pylori</i> Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability. <i>American Journal of Gastroenterology</i> , 2010, 105, 65-73.	0.2	188
21	Can the Clinical History Distinguish Between Organic and Functional Dyspepsia?. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1566.	3.8	167
22	Clinical effectiveness of laparoscopic fundoplication in a U.S. community. <i>American Journal of Medicine</i> , 2003, 114, 1-5.	0.6	161
23	Seven-day therapy for <i>Helicobacter pylori</i> in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 99-107.	1.9	146
24	BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015, 110, 662-682.	0.2	116
25	Human tissue responses to metal stents implanted in vivo for the palliation of malignant stenoses. <i>Gastrointestinal Endoscopy</i> , 1996, 43, 596-602.	0.5	110
26	The Stool Antigen Test for Detection of <i>Helicobacter pylori</i> after Eradication Therapy. <i>Annals of Internal Medicine</i> , 2002, 136, 280.	2.0	104
27	Limited Ability of the Proton-Pump Inhibitor Test to Identify Patients With Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1360-1366.	2.4	103
28	<i>Helicobacter pylori</i> and reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 297-305.	1.9	99
29	Clarithromycin-Resistant <i>Helicobacter pylori</i> in Patients With Duodenal Ulcer in the United States. <i>American Journal of Gastroenterology</i> , 1998, 93, 1432-1435.	0.2	89
30	Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 45-51.	1.9	87
31	Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials. <i>American Journal of Gastroenterology</i> , 2008, 103, ???-???	0.2	82
32	A prospective trial of self-expanding metal stents in the palliation of malignant esophageal obstruction after failure of primary curative therapy. <i>Gastrointestinal Endoscopy</i> , 1996, 44, 283-286.	0.5	80
33	New pharmacological agents for the treatment of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 1041-1049.	1.9	73
34	Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 559-568.	1.9	71
35	Review article: how valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 64-69.	1.9	71
36	Upper GI malignancy, uncomplicated dyspepsia, and the age threshold for early endoscopy. <i>American Journal of Gastroenterology</i> , 2002, 97, 600-603.	0.2	66

#	ARTICLE	IF	CITATIONS
37	Disease definition, clinical manifestations, epidemiology and natural history of GERD. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 759-764.	1.0	65
38	A prospective trial of self-expanding metal stents in the palliation of malignant esophageal strictures near the upper esophageal sphincter. <i>Gastrointestinal Endoscopy</i> , 1997, 45, 300-303.	0.5	60
39	A Prospective Trial of a New Self-Expanding Plastic Stent for Malignant Esophageal Obstruction. <i>American Journal of Gastroenterology</i> , 2001, 96, 1350-1354.	0.2	60
40	Symptom Overlap Between Postprandial Distress and Epigastric Pain Syndromes of the Rome III Dyspepsia Classification. <i>American Journal of Gastroenterology</i> , 2013, 108, 767-774.	0.2	58
41	Cost of Detecting Malignant Lesions by Endoscopy in 2741 Primary Care Dyspeptic Patients Without Alarm Symptoms. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 756-761.	2.4	55
42	<i>Helicobacter pylori</i> Treatment: A Practical Approach. <i>American Journal of Gastroenterology</i> , 2006, 101, 497-499.	0.2	54
43	Editorial: <i>H. pylori</i> Treatment: New Wine in Old Bottles?. <i>American Journal of Gastroenterology</i> , 2009, 104, 26-30.	0.2	54
44	Short- and long-term outcome of esophageal perforation. <i>Gastrointestinal Endoscopy</i> , 1995, 41, 130-134.	0.5	53
45	Prescribing Proton Pump Inhibitors. <i>Drugs</i> , 2012, 72, 437-445.	4.9	53
46	Culture-based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for <i>Helicobacter pylori</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 507-510.	2.4	53
47	Sequential therapy for <i>Helicobacter pylori</i> eradication: the time is now!. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 317-322.	1.4	52
48	Treatment for <i>H. pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 383-388.	1.1	52
49	Cost Savings in Duodenal Ulcer Therapy Through <i>Helicobacter pylori</i> Eradication Compared With Conventional Therapies<subtitle>Results of a Randomized, Double-blind, Multicenter Trial</subtitle>. <i>Archives of Internal Medicine</i> , 1998, 158, 852.	4.3	48
50	The cost-effectiveness of diagnostic testing strategies for. <i>American Journal of Gastroenterology</i> , 2000, 95, 1691-1698.	0.2	47
51	Effect of push enteroscopy on transfusion requirements and quality of life in patients with unexplained gastrointestinal bleeding. <i>American Journal of Gastroenterology</i> , 1997, 92, 425-8.	0.2	47
52	Human Tissue Responses to Metal Stents. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1999, 9, 359-365.	0.6	45
53	Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. <i>United European Gastroenterology Journal</i> , 2016, 4, 413-422.	1.6	43
54	Proton Pump Inhibitors and the Time Trends for Esophageal Dilation. <i>American Journal of Gastroenterology</i> , 2004, 99, 797-800.	0.2	42

#	ARTICLE	IF	CITATIONS
55	Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 673-682.	1.9	41
56	Epithelial Thickness is a Marker of Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1544-1551.e1.	2.4	41
57	Review article: the role of surgery in gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1365-1372.	1.9	39
58	Patterns of gastritis and the effect of eradicating <i>Helicobacter pylori</i> on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 55-63.	1.9	36
59	Ten-Day Triple Therapy With Ranitidine Bismuth Citrate, Amoxicillin, and Clarithromycin in Eradicating <i>Helicobacter Pylori</i> . <i>American Journal of Gastroenterology</i> , 1999, 94, 1197-1199.	0.2	35
60	Funding Source and Conflict of Interest Disclosures by Authors and Editors in Gastroenterology Specialty Journals. <i>American Journal of Gastroenterology</i> , 2007, 102, 1146-1150.	0.2	35
61	Symptomatic gastro-oesophageal reflux, arousals and sleep quality in patients undergoing polysomnography for possible obstructive sleep apnoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1153-1159.	1.9	33
62	Acid Inhibition and Infections Outside the Gastrointestinal Tract. <i>American Journal of Gastroenterology</i> , 2009, 104, S17-S20.	0.2	33
63	Cost-effectiveness of treatment regimens for the eradication of <i>Helicobacter pylori</i> in duodenal ulcer. <i>American Journal of Gastroenterology</i> , 1996, 91, 239-45.	0.2	33
64	Rifabutin Triple Therapy is Effective in Patients With Multidrug-resistant Strains of <i>Helicobacter pylori</i> . <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 137-140.	1.1	32
65	Mortality and complications following surgery for diverticulitis: Systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2016, 4, 706-713.	1.6	31
66	Effect of <i>Helicobacter pylori</i> eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. <i>Gut</i> , 2003, 52, 1543-1547.	6.1	28
67	IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. <i>Gastroenterology</i> , 2020, 158, 2093-2103.	0.6	28
68	Sequential Therapy for <i>Helicobacter pylori</i> . <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1346.	3.8	26
69	Clinical trial design in adult reflux disease: a methodological workshop. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 107-126.	1.9	25
70	One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8-weeks treatment with esomeprazole: a randomized, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 665-672.	1.9	24
71	Endoscopy in GERD: Boondoggle, Diagnostic Test, or Risk Management Tool?. <i>American Journal of Gastroenterology</i> , 2008, 103, 276-278.	0.2	23
72	Glucagon Is a Safe and Inexpensive Initial Strategy in Esophageal Food Bolus Impaction. <i>Digestive Diseases and Sciences</i> , 2016, 61, 841-845.	1.1	21

#	ARTICLE	IF	CITATIONS
73	Measurement of Lesions by Endoscopy: An Overview. <i>Endoscopy</i> , 1995, 27, 694-697.	1.0	20
74	Are There Geographical and Regional Differences in <i>Helicobacter pylori</i> Eradication?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003, 17, 30B-32B.	1.8	18
75	Comprehension and awareness of symptoms in women with dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 1147-1155.	1.9	18
76	Validation of the Reflux Symptom Questionnaire Electronic Diary in Partial Responders to Proton Pump Inhibitor Therapy. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e7.	1.3	18
77	Can famotidine and omeprazole be combined on a once-daily basis?. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 689-694.	0.6	17
78	An International Primary Care Survey of GERD Terminology and Guidelines. <i>Digestive Diseases</i> , 2008, 26, 231-236.	0.8	17
79	Approach to gastroesophageal reflux disease in primary care: Putting the Montreal definition into practice. <i>Canadian Family Physician</i> , 2008, 54, 701-5.	0.1	17
80	Pneumatic Dilation in Achalasia. <i>Endoscopy</i> , 2003, 35, 526-530.	1.0	16
81	Unrecognized GERD Symptoms Are Associated with Excessive Daytime Sleepiness in Patients Undergoing Sleep Studies. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2873-2876.	1.1	16
82	Sleep disturbance due to heartburn and regurgitation is common in patients with functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2016, 4, 191-198.	1.6	16
83	The effect of over-the-counter ranitidine 75 mg on night-time heartburn in patients with erosive oesophagitis on daily proton pump inhibitor maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 649-653.	1.9	15
84	Diagnosis of gastro-oesophageal reflux disease is enhanced by adding oesophageal histology and excluding epigastric pain. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1350-1357.	1.9	15
85	Systematic review: patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1469-1480.	1.9	14
86	Endoscopic treatments for gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1427-1434.	1.9	14
87	<i>Helicobacter pylori</i> Eradication: Equivalence Trials and the Optimal Duration of Therapy. <i>American Journal of Gastroenterology</i> , 2005, 100, 1702-1703.	0.2	14
88	The Frontiers of Reflux Disease. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1887-1895.	1.1	14
89	The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 394-408.	0.8	14
90	Metal stents for malignant esophageal obstruction. <i>American Journal of Gastroenterology</i> , 1996, 91, 2471-6.	0.2	14

#	ARTICLE	IF	CITATIONS
91	Human tissue responses to metal stents. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1999, 9, 359-65.	0.6	14
92	Cost-effectiveness of different GERD management strategies. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 79-82.	1.9	13
93	Review article: esomeprazole, 40mg once daily, compared with lansoprazole, 30mg once daily, in healing and symptom resolution of erosive oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 21-23.	1.9	13
94	Test and treat or treat and test in reflux disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 57-59.	1.9	13
95	Duplicate breath testing to confirm eradication of <i>Helicobacter pylori</i> : incremental benefit and cost in 419 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1304-1308.	1.9	13
96	Dyspepsia, Peptic Ulcer, and <i>H. pylori</i> : A Remembrance of Things Past. <i>American Journal of Gastroenterology</i> , 2010, 105, 572-574.	0.2	13
97	Funding source and conflict of interest disclosures by authors and editors in gastroenterology specialty journals revisited. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 690-695.	1.9	13
98	The initial diagnosis of GERD. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 365-371.	1.0	13
99	Dietary Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAPs) and Gastrointestinal Disease. <i>Nutrition in Clinical Practice</i> , 2018, 33, 468-475.	1.1	13
100	Multitarget stool DNA testing for the prevention of colon cancer: outcomes in a large integrated healthcare system. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 334-341.	0.5	11
101	Non-invasive tests for the diagnosis of <i>H. pylori</i> infection. <i>Reviews in Gastroenterological Disorders</i> , 2004, 4, 1-6.	0.6	9
102	Gender differences in symptoms in partial responders to proton pump inhibitors for gastroesophageal reflux disease. <i>United European Gastroenterology Journal</i> , 2015, 3, 443-452.	1.6	8
103	Salivary pepsin to diagnose GORD?. <i>Gut</i> , 2015, 64, 361-362.	6.1	8
104	Proton Pump Inhibitors for Dyspepsia. <i>Digestive Diseases</i> , 2008, 26, 215-217.	0.8	7
105	Expandable Metal Stents: Principles and Tissue Responses. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 351-357.	0.6	7
106	Development and validation of a patient-reported outcome instrument in partial responders to proton pump inhibitors. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1018-1026.	0.6	6
107	Is the stool test out of breath?. <i>Digestive and Liver Disease</i> , 2000, 32, 291-293.	0.4	5
108	Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis of two study populations. <i>BMC Gastroenterology</i> , 2014, 14, 177.	0.8	5

#	ARTICLE	IF	CITATIONS
109	Prevalence of gastroesophageal reflux disease with upper gastrointestinal symptoms without heartburn and regurgitation. <i>United European Gastroenterology Journal</i> , 2014, 2, 173-178.	1.6	5
110	Colorectal cancer in 18- to 49-year-olds: rising rates, presentation, and outcome in a large integrated health system. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 618-626.	0.5	5
111	<i>Helicobacter pylori</i> treatment: is sequential or quadruple therapy the answer?. <i>Reviews in Gastroenterological Disorders</i> , 2008, 8, 77-82.	0.6	5
112	Pretreatment Endoscopy - Pro & Contra: Is Endoscopy Needed before Treatment in All Patients with Gastroesophageal Reflux Disease?. <i>Endoscopy</i> , 2006, 38, 276-278.	1.0	4
113	Body Mass Index and Gastroesophageal Reflux Disease: Implications of the Obesity Epidemic. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2291-2292.	1.1	4
114	Microbiome: In Search of Mechanistic Information and Relevance. <i>American Journal of Gastroenterology</i> , 2019, 114, 1014-1016.	0.2	4
115	How to test for <i>Helicobacter pylori</i> in 2005.. <i>Cleveland Clinic Journal of Medicine</i> , 2005, 72, S8-S8.	0.6	4
116	Gastroesophageal reflux disease and <i>Helicobacter pylori</i> infection. <i>Reviews in Gastroenterological Disorders</i> , 2003, 3, 1-7.	0.6	4
117	The prevention of gastropathy and upper abdominal symptoms caused by nonsteroidal anti-inflammatory drugs. <i>Reviews in Gastroenterological Disorders</i> , 2006, 6, 221-6.	0.6	4
118	Nonulcer dyspepsia. <i>Current Gastroenterology Reports</i> , 2002, 4, 455-458.	1.1	3
119	Long-term strategies. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 853-856.	0.8	3
120	COMMENTARY: Toward a simplified strategy for managing dyspepsia. <i>Postgraduate Medicine</i> , 2005, 117, 13-16.	0.9	3
121	New pharmacological agents for the treatment of gastroesophageal reflux disease. <i>Reviews in Gastroenterological Disorders</i> , 2008, 8, 117-22.	0.6	3
122	Endoscopic Measurement of Lesion Size. <i>Digestive Endoscopy</i> , 1999, 11, 193-197.	1.3	2
123	Esophageal cancer. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 486-489.	1.0	2
124	Novel methods of using proton-pump inhibitors. <i>Gastroenterology Clinics of North America</i> , 2002, 31, S85-S88.	1.0	2
125	A BALANCING VIEW: Endoscopy in Dyspepsia: A Tale of Two Cities. <i>American Journal of Gastroenterology</i> , 2007, 102, 476-477.	0.2	2
126	Aerobic exercise and caloric reduction should be the key lifestyle modifications in obese patients with GERD. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1133-1134.	1.9	2

#	ARTICLE	IF	CITATIONS
127	Editorial: baclofen and transient lower oesophageal sphincter relaxations – the band plays on. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1360-1361.	1.9	2
128	Editorial: alginate-antacid combinations in erosive oesophagitis - picking the acid pocket. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1232-1232.	1.9	2
129	Editorial: population-based testing for <i>Helicobacter pylori</i> in Western countries. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1360-1360.	1.9	2
130	<i>Helicobacter pylori</i> . Can <i>Helicobacter pylori</i> infection prevent allergic asthma?. <i>Reviews in Gastroenterological Disorders</i> , 2009, 9, E66-7.	0.6	2
131	Antimicrobial resistance and eradication strategies for <i>Helicobacter pylori</i> . <i>Reviews in Gastroenterological Disorders</i> , 2009, 9, E78-83.	0.6	2
132	An overview of the success and failure of surgical therapy: standards against which the outcome of endoscopic therapy is measured. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2003, 13, 69-73.	0.6	1
133	Rationale for a <i>Helicobacter pylori</i> Test and Treatment Strategy in Gastroesophageal Reflux Disease. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 661-666.	1.0	1
134	Editorial: quadruple therapy for <i>H. pylori</i> eradication is better than triple therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 694-695.	1.9	1
135	Editorial: alginates for inadequate response to a proton pump inhibitor in gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1103-1103.	1.9	1
136	Editorial: functional dyspepsia – a disorder of duodenal permeability?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 70-71.	1.9	1
137	Editorial: selective serotonin receptor inhibitors and gastrointestinal bleeding – managing the risk. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 552-553.	1.9	1
138	Treatment of <i>H. pylori</i> infection: the reality. <i>Yale Journal of Biology and Medicine</i> , 1998, 71, 119-24.	0.2	1
139	Epigastric pain in dyspepsia and reflux disease. <i>Reviews in Gastroenterological Disorders</i> , 2003, 3 Suppl 4, S16-21.	0.6	1
140	Increasing compliance with long-term therapy: avoiding complications and adverse events. <i>Reviews in Gastroenterological Disorders</i> , 2005, 5 Suppl 2, S12-7.	0.6	1
141	New developments in the treatment of <i>Helicobacter pylori</i> : is sequential therapy the answer?. <i>Reviews in Gastroenterological Disorders</i> , 2008, 8, 217-8.	0.6	1
142	<i>Helicobacter pylori</i> and non-ulcer dyspepsia. <i>Current Treatment Options in Gastroenterology</i> , 2000, 3, 341-345.	0.3	0
143	Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. <i>Clinical Otolaryngology</i> , 2008, 33, 114-114.	0.6	0
144	Commentary: balloon distension of the oesophagus – not ready for primetime. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 202-203.	1.9	0

#	ARTICLE	IF	CITATIONS
145	Response to Tack and Carbone. American Journal of Gastroenterology, 2013, 108, 1810.	0.2	0
146	Commentary: tegaserod and IBS, two decades on. Alimentary Pharmacology and Therapeutics, 2020, 51, 200-201.	1.9	0
147	Endoscopic imaging technology. Gastrointestinal Endoscopy Clinics of North America, 1994, 4, 463-73.	0.6	0
148	Dyspepsia, non-ulcer dyspepsia, and Helicobacter pylori. Reviews in Gastroenterological Disorders, 2001, 1, 139-46.	0.6	0
149	The potential dangers of test-and-treat strategies directed at H. pylori. Reviews in Gastroenterological Disorders, 2004, 4, 94-5.	0.6	0